Skip to main content

Table 7 Association between different parameters and median EFS rate in osteosarcoma patients treated with cisplatin combinations

From: The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

The studied parameter

Median EFS time in years

Log rank

Tumor location

Arm

1.49

0.477

Femur

1.70

Tibia

2.29

Others

1.73

Presence of metastasis

No metastasis

2.04

0.071

With metastasis

0.750

Gender

Male

2.04

0.289

Female

1.16

Histological subtypes

Conventional

2.04

0.039

Variant

1.00

Type of chemotherapy

MAP

1.73

0.432

Cisplatin & doxorubicin

1.42

Others

3.07

Response

Poor response

1.42

0.189

Good response

3.07

Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us